Maximus (NYSE:MMS) Director Jan Madsen Sells 742 Shares of Stock

Maximus, Inc. (NYSE:MMS) Director Jan Madsen sold 742 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $72.25, for a total value of $53,609.50. Following the sale, the director owned 20,795 shares of the company’s stock, valued at $1,502,438.75. This trade represents a 3.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Maximus Stock Up 0.8%

MMS opened at $72.11 on Wednesday. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.34 and a quick ratio of 2.34. The firm has a market capitalization of $3.93 billion, a P/E ratio of 10.98 and a beta of 0.59. Maximus, Inc. has a fifty-two week low of $64.68 and a fifty-two week high of $100.00. The company’s 50-day moving average is $83.80 and its 200 day moving average is $85.44.

Maximus (NYSE:MMS) last posted its earnings results on Thursday, February 5th. The health services provider reported $1.85 EPS for the quarter, topping the consensus estimate of $1.84 by $0.01. The firm had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.37 billion. Maximus had a net margin of 6.92% and a return on equity of 25.30%. The company’s quarterly revenue was down 4.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.61 EPS. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS. Research analysts expect that Maximus, Inc. will post 6.15 earnings per share for the current fiscal year.

Maximus Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were given a dividend of $0.33 per share. The ex-dividend date was Friday, February 13th. This is an increase from Maximus’s previous quarterly dividend of $0.30. This represents a $1.32 annualized dividend and a yield of 1.8%. Maximus’s dividend payout ratio (DPR) is currently 20.09%.

Hedge Funds Weigh In On Maximus

Institutional investors have recently bought and sold shares of the stock. Magnetar Financial LLC increased its holdings in shares of Maximus by 123.5% during the second quarter. Magnetar Financial LLC now owns 12,774 shares of the health services provider’s stock valued at $897,000 after acquiring an additional 7,059 shares in the last quarter. Deprince Race & Zollo Inc. raised its holdings in shares of Maximus by 147.1% during the third quarter. Deprince Race & Zollo Inc. now owns 243,695 shares of the health services provider’s stock valued at $22,266,000 after purchasing an additional 145,062 shares during the last quarter. Boston Partners lifted its holdings in shares of Maximus by 113.6% during the 2nd quarter. Boston Partners now owns 657,247 shares of the health services provider’s stock valued at $46,435,000 after buying an additional 349,529 shares during the period. JPMorgan Chase & Co. lifted its holdings in Maximus by 19.8% in the third quarter. JPMorgan Chase & Co. now owns 200,331 shares of the health services provider’s stock valued at $18,304,000 after acquiring an additional 33,136 shares during the period. Finally, Creative Planning lifted its stake in shares of Maximus by 77.1% in the 2nd quarter. Creative Planning now owns 37,582 shares of the health services provider’s stock worth $2,638,000 after purchasing an additional 16,363 shares during the period. 97.21% of the stock is owned by institutional investors.

Analysts Set New Price Targets

MMS has been the topic of a number of research reports. Weiss Ratings cut Maximus from a “buy (b)” rating to a “hold (c+)” rating in a research note on Tuesday, February 24th. Wall Street Zen cut shares of Maximus from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Finally, Zacks Research raised shares of Maximus from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 30th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy”.

Maximus Company Profile

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.